These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36400098)

  • 21. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
    Chang JY; Mehran RJ; Feng L; Verma V; Liao Z; Welsh JW; Lin SH; O'Reilly MS; Jeter MD; Balter PA; McRae SE; Berry D; Heymach JV; Roth JA;
    Lancet Oncol; 2021 Oct; 22(10):1448-1457. PubMed ID: 34529930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations.
    Correa RJM; Rodrigues GB; Chen H; Warner A; Ahmad B; Louie AV
    Am J Clin Oncol; 2018 Jun; 41(6):568-575. PubMed ID: 27635623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma in Non-surgical Candidates: Initial Clinical Experience.
    Chang JH; Cheung P; Erler D; Sonier M; Korol R; Chu W
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e109-14. PubMed ID: 27131756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS).
    Siva S; Louie AV; Kotecha R; Barber MN; Ali M; Zhang Z; Guckenberger M; Kim MS; Scorsetti M; Tree AC; Slotman BJ; Sahgal A; Lo SS
    Lancet Oncol; 2024 Jan; 25(1):e18-e28. PubMed ID: 38181809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial.
    Siva S; Pham D; Kron T; Bressel M; Lam J; Tan TH; Chesson B; Shaw M; Chander S; Gill S; Brook NR; Lawrentschuk N; Murphy DG; Foroudi F
    BJU Int; 2017 Nov; 120(5):623-630. PubMed ID: 28188682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies.
    Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S
    Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma.
    Reynolds HM; Parameswaran BK; Finnegan ME; Roettger D; Lau E; Kron T; Shaw M; Chander S; Siva S
    PLoS One; 2018; 13(8):e0202387. PubMed ID: 30114235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer.
    Ali M; Kwon YS; Koo K; Bruynzeel A; Pryor D; Schep DG; Huo M; Stein M; Swaminath A; Hannan R; Siva S
    BJU Int; 2025 Jan; 135(1):110-116. PubMed ID: 39187428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma.
    Raj RK; Upadhyay R; Wang SJ; Singer EA; Dason S
    Curr Oncol; 2023 Dec; 30(12):10283-10298. PubMed ID: 38132383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.
    Siva S; Bressel M; Mai T; Le H; Vinod S; de Silva H; Macdonald S; Skala M; Hardcastle N; Rezo A; Pryor D; Gill S; Higgs B; Wagenfuehr K; Montgomery R; Awad R; Chesson B; Eade T; Wong W; Sasso G; De Abreu Lourenco R; Kron T; Ball D; Neeson P;
    JAMA Oncol; 2021 Oct; 7(10):1476-1485. PubMed ID: 34455431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study.
    Chalkidou A; Macmillan T; Grzeda MT; Peacock J; Summers J; Eddy S; Coker B; Patrick H; Powell H; Berry L; Webster G; Ostler P; Dickinson PD; Hatton MQ; Henry A; Keevil S; Hawkins MA; Slevin N; van As N
    Lancet Oncol; 2021 Jan; 22(1):98-106. PubMed ID: 33387498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
    Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotactic Body Radiotherapy for Renal Cell Carcinoma: Oncological and Renal Function Outcomes.
    Glicksman RM; Cheung P; Korol R; Niglas M; Nusrat H; Erler D; Vesprini D; Swaminath A; Davidson M; Zhang L; Chu W
    Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):20-28. PubMed ID: 35948465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus.
    Freifeld Y; Pedrosa I; Mclaughlin M; Correa RM; Louie AV; Maldonado JA; Tang C; Kadow B; Kutikov A; Uzzo RG; Porta C; Bucknell NW; Siva S; Brugarolas J; Margulis V; Timmerman R; Hannan R
    Urol Oncol; 2022 Apr; 40(4):166.e9-166.e13. PubMed ID: 35144866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.
    Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J
    Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First UK patient cohort treated with stereotactic ablative radiotherapy for primary kidney cancer.
    Zarkar A; Henderson D; Carver A; Heyes G; Harrop V; Tutill S; Kilkenny J; Marshall A; Elbeltagi N; Howard H
    BJUI Compass; 2023 Jul; 4(4):464-472. PubMed ID: 37334027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma.
    Khriguian J; Patrocinio H; Andonian S; Aprikian A; Kassouf W; Tanguay S; Cury FL
    Pract Radiat Oncol; 2022; 12(1):e34-e39. PubMed ID: 34530170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients.
    Ma MW; Li HZ; Gao XS; Liu MZ; Yin H; Yang KW; Chen JY; Ren XY; Wang D
    Curr Oncol; 2022 Oct; 29(10):7832-7841. PubMed ID: 36290896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
    Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
    Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CyberKnife for inoperable renal tumors: Canadian pioneering experience.
    Nair VJ; Szanto J; Vandervoort E; Cagiannos I; Breau R; Malone C; Avruch L; Pantarotto J; Malone S
    Can J Urol; 2013 Oct; 20(5):6944-9. PubMed ID: 24128835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.